Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amyris, Inc.
Appointments: GSK, Neurocrine Biosciences, Cue Biopharma, BenevolentAI And Ferring Pharmaceuticals
This week's roundup includes two executive appointments by GSK, plus updates from Radius Health Inc., Cue Biopharma and BenevolentAI, with Myovant Sciences making four key management hires.
Appointments: Gilead, Biogen, Nordic Nanovector, Neon Therapeutics, Achaogen and vasopharm
This week's roundup includes executive appointments by Gilead Sciences, Nordic Nanovector, Mereo BioPharma, vasopharm and Rigontec. Biogen has also appointed two executives to its planned spin-off company, Bioverativ.
Synthetic Biology And The Computerization Of Drug Development
Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.
Deals Shaping The Medical Industry, March 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2016.
- Digital Health
- OTC, Consumer
- Antisense, Oligonucleotides
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Natural Products
- Molecular Diversity
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.